Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NYSE]
Sanofi
Index- P/E23.82 EPS (ttm)1.71 Insider Own16.40% Shs Outstand2.53B Perf Week-0.71%
Market Cap103.13B Forward P/E13.84 EPS next Y2.95 Insider Trans0.00% Shs Float2.31B Perf Month3.27%
Income4.45B PEG3.78 EPS next Q0.63 Inst Own10.80% Short Float0.16% Perf Quarter9.13%
Sales36.44B P/S2.83 EPS this Y4.10% Inst Trans-0.45% Short Ratio1.63 Perf Half Y-1.04%
Book/sh22.23 P/B1.83 EPS next Y-3.60% ROA- Target Price48.67 Perf Year5.21%
Cash/sh- P/C- EPS next 5Y6.30% ROE- 52W Range36.11 - 42.75 Perf YTD0.79%
Dividend1.66 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-5.94% Beta0.98
Dividend %4.07% Quick Ratio- Sales past 5Y0.50% Gross Margin69.10% 52W Low11.35% ATR0.77
Employees115631 Current Ratio- Sales Q/Q2.60% Oper. Margin17.80% RSI (14)47.42 Volatility1.64% 1.30%
OptionableYes Debt/Eq- EPS Q/Q3.90% Profit Margin14.60% Rel Volume0.60 Prev Close40.76
ShortableYes LT Debt/Eq- EarningsFeb 08 BMO Payout0.00% Avg Volume2.22M Price40.21
Recom1.70 SMA20-0.15% SMA50-0.27% SMA2000.47% Volume500,409 Change-1.35%
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Jan-18-17 03:56PM  MannKind Has a New Plan, but Will It Work? at Motley Fool
08:45AM  Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval
Jan-17-17 04:43PM  Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad
01:22PM  Sanofi: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes GlobeNewswire
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-16-17 09:07AM  How Did Novartis Perform in 3Q16?
08:38AM  5 Trump-Proof Pharma Dividends Up To 5.3% at Forbes
Jan-15-17 07:10AM  Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016 at Motley Fool
Jan-13-17 04:32PM  Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink
09:30AM  Sanofi, ImmuNext Sign $500M Autoimmune Drug Pact at Investopedia
Jan-12-17 04:00PM  Insulin Drug Offers Hope for MannKind
12:04PM  Regeneron, Sanofi's Drug Manufacturing Plant Cleared at Investopedia
10:37AM  Mylans Specialty Segment: The Effect of Falling EpiPen Sales
Jan-11-17 05:05PM  Mylans EpiPen Controversy: Is It a Brand or a Generic?
Jan-10-17 06:25PM  Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals
08:53AM  2 Top Stocks in Biotech at Motley Fool
08:51AM  Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit
Jan-09-17 01:36PM  Sanofi Sees No Opening to Actelion Talks After J&J Re-Entry at Bloomberg
01:30PM  Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries at Barrons.com
08:11AM  Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
08:00AM  Sanofi and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune Diseases PR Newswire
Jan-08-17 11:54PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
02:02PM  Why Biotech Titans Are Clashing Over Cholesterol at Motley Fool
Jan-07-17 10:53AM  In the age of Uber and Lyft, its still hard for some Americans to get to the doctor at MarketWatch
10:47AM  Judges unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake at MarketWatch
Jan-06-17 07:33PM  Sanofi Investors Count Cost of Praluent Ruling at The Wall Street Journal
06:41PM  Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today at Motley Fool
04:56PM  [$$] Amgen Patent Win Boosts Odds of a Stock Comeback at Barrons.com
04:22PM  Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
04:13PM  Regeneron, Sanofi Hammered After Judge Bans Amgen-Rivaling LDL-Buster
02:12PM  Regeneron: Let's Make a Deal? at Barrons.com
01:59PM  Sanofi Counts Cost of Ruling That Blocks Its Cholesterol Drug at The Wall Street Journal
01:23PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
12:57PM  Regeneron shares fall after judge blocks selling of cholesterol-lowering drug at CNBC
11:56AM  European stocks pare losses after U.S. jobs report at MarketWatch
11:55AM  Fridays 6 Biopharma Movers That Cant Be Ignored
11:47AM  [$$] Regeneron shares tumble as US court blocks cholesterol drug at Financial Times
10:16AM  Regeneron, Sanofi Cholesterol Drug Gets Blocked at Investopedia
10:13AM  [video]Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
10:04AM  Gap soars on holiday sales cheer, Amgen jumps on patent win, Apple to open store in Samsung's home turf
08:13AM  Jobs growth disappoints, wages soar
07:45AM  Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent
07:24AM  Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
05:53AM  Sanofi Investors Have Worst Day in Six Months
05:50AM  Regeneron Cholesterol-Lowering Drug Banned From U.S. Market in Stunning Loss to Amgen in Patent Case
Jan-05-17 10:49PM  Sanofi and Regeneron to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection GlobeNewswire
08:00PM  Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection PR Newswire
05:52PM  Sanofi, Regeneron blocked from selling cholesterol drug
04:46PM  Amgen Wins Ban on Sanofis Praluent Cholesterol Drug Sales at Bloomberg
12:24AM  Business Watch at The Wall Street Journal
Jan-04-17 04:09PM  Regeneron, Sanofi LDL-Buster At Risk After Judge Upholds Amgen Patents
02:30PM  Amgen Keeps Cholesterol Drug Patent Vs Regeneron at Investopedia
11:47AM  GM shares jump on sales climb; Tesla deliveries fall short; Oppenheimer says buy Panera Bread
11:09AM  Sanofi SA (ADR) (SNY) Hit With Cease And Desist Order On Dengue Vaccine Ads In The Philippines at Insider Monkey
11:06AM  Regeneron: Who Cares If Amgen Won the Latest Patent Battle? at Barrons.com
09:34AM  Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit
Jan-03-17 04:45PM  Sanofi (SNY) Closes Business Exchange Deal with Boehringer
01:45PM  With Sanofi swap done, Boehringer Ingelheim leads U.S. pet health at bizjournals.com
01:14PM  Mylan NV (MYL), AbbVie Inc (ABBV) Sanofi SA (ADR) (SNY) In Spotlight Over Price Hikes at Insider Monkey
04:45AM  Philippine FDA orders Sanofi to take down dengue vaccine ads
Jan-02-17 09:06AM  GlaxoSmithKlines Vaccines Business
01:55AM  Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017 Business Wire
Dec-30-16 08:57AM  Regulator Demands Divestiture In Asset Swap Deal Between Boehringer, Sanofi SA (ADR) (SNY) at Insider Monkey
07:37AM  Cystic Fibrosis Strategy: Will It Boost Vertexs Future Revenues?
Dec-29-16 03:05PM  Orkambi Is Still Strong Revenue Driver for Vertex Pharmaceuticals
08:25AM  Early movers: S, SNY, ALR, TWTR, MYL, AAPL & more at CNBC
07:35AM  Why Did Valeant Pharmaceuticals Update Its 2016 EPS Guidance?
Dec-28-16 10:30PM  U.S. FTC requires divestitures in $13.53 billion Boehringer-Sanofi deal Reuters
05:12PM  FTC requires divestitures in $13.53 billion Boehringer-Sanofi deal Reuters
03:43PM  Sanofi SA (ADR) (SNY) Files Suit Against Novo Nordisk A/S (ADR) (NVO) Over False Insulin Claims at Insider Monkey
02:26PM  U.S. FTC requires divestitures in $13.53 bln Boehringer-Sanofi deal Reuters
05:29AM  Boehringer to divest US assets to win approval for Sanofi deal AFP
Dec-27-16 11:36AM  Sanofi sues Novo Nordisk over diabetes drugs in the U.S.
Dec-23-16 07:00AM  Guess who bought this giant old Marion Labs plant at bizjournals.com
Dec-22-16 10:58AM  Actelion's Fate May Rest on Structure, Not Price, as Clozel Holds Firm
09:28AM  [$$] Johnson & Johnson Back in Exclusive Talks for Actelion at The Wall Street Journal
07:58AM  J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?
03:37AM  European Stocks Drift Lower in Holiday-Thinned Trading
03:25AM  European shares pull back, Actelion hits record high
12:19AM  [$$] Johnson & Johnson Back in Exclusive Talks for Actelion at The Wall Street Journal
Dec-21-16 04:19PM  Johnson & Johnson In Exclusive Talks To Acquire Actelion After Sanofi Fray
03:08PM  What Inovio Pharmaceuticals' Latest Zika News Means for Investors at Motley Fool
01:42PM  Actelion re-enters talks with J&J, sidelining Sanofi
12:17PM  Actelion Restarts Possible Merger Talks With Johnson & Johnson
11:44AM  Actelion, J&J Are Back in Talks a Week After Breakup at Bloomberg
09:05AM  Understanding Horizon Pharmas Revenue Growth beyond 2016
08:30AM  Actelion Shares Rise Amid Speculation on Possible Improved Sanofi Bid
04:21AM  Actelion shares gain on report of progress in Sanofi talks
Dec-20-16 04:32PM  Regeneron Likely To Jump On Amgen LDL-Buster, But Expectations Too High
03:00PM  These Mass. biotechs saw drugs get FDA approval in 2016 at bizjournals.com
02:01PM  Sanofi's takeover talks with Actelion progressing: source
01:55PM  Sanofi's takeover talks with Actelion progressing - source
12:33PM  Sanofi talks with Actelion progressing - source
12:09PM  How Oculus Lost Market Leadership -- And How It Can Win It Back at Forbes
Dec-19-16 05:42PM  Dodge & Cox Invests in 7 Positions in the 3rd Quarter
04:27PM  Analysts Mixed on Healthcare Stocks in the New Year
02:26PM  Big pharmas new playbook for a scandal-free 2017 at MarketWatch
12:56PM  Mexico raises cough medicine objection to Sanofi-Boehringer deal Reuters
12:25PM  Innate Pharma Pops as It Names AstraZeneca's Oncology Head as Chairman
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJan 11Buy369.7187,29832,274,87223,505,694Jan 13 04:15 PM
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM